Medication Guide - 7/10/2026

 

Medication guides are FDA- approved documents that address issues that are specific to particular drugs, and can help patients avoid serious adverse events (side effects). This database does not include Medication Guides for FDA-approved allergenic or cellular/tissue products (see  FDA Online Label Repository  or DailyMed  for these Medication Guides).  More

Drug Name Active Ingredient Form;Route Appl. No. Company Date
Anzupgo Delgocitinib CREAM 219155 LEO PHARMA AS 07/10/2026
Mayzent Siponimod Fumaric Acid TABLET;ORAL 209884 NOVARTIS 07/10/2026
Olumiant Baricitinib TABLET;ORAL 207924 ELI LILLY AND CO 07/10/2026
Opzelura Ruxolitinib Phosphate CREAM;TOPICAL 215309 INCYTE CORP 07/10/2026
Rinvoq Upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675 ABBVIE INC 07/10/2026
Soliris Eculizumab INJECTABLE; IV (INFUSION) 125166 ALEXION PHARM 07/10/2026
Sotyktu Deucravacitinib TABLET;ORAL 214958 BRISTOL MYERS SQUIBB 07/10/2026
Strattera Atomoxetine Hydrochloride CAPSULE;ORAL 021411 LILLY 07/10/2026
Tascenso ODT Fingolimod LAuryl Sulfate TABLET, ORALLY DISINTEGRATING;ORAL 214962 HANDA NEUROSCIENCE, LTD 07/10/2026
Xeljanz Tofacitinib Citrate SOLUTION;ORAL 213082 PFIZER 07/10/2026
Xeljanz Tofacitinib Citrate TABLET;ORAL 203214 PF PRISM CV 07/10/2026
Xeljanz XR Tofacitinib Citrate TABLET, EXTENDED RELEASE;ORAL 208246 PFIZER 07/10/2026
Adderall XR 10 Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303 TAKEDA PHARMS USA 06/23/2026
Vyvanse Lisdexamfetamine Dimesylate CAPSULE;ORAL 021977 TAKEDA PHARMS USA 06/23/2026
Vyvanse Lisdexamfetamine Dimesylate TABLET, CHEWABLE;ORAL 208510 TAKEDA PHARMS USA 06/23/2026
Yervoy Ipilimumab INJECTABLE; INJECTION 125377 BRISTOL MYERS SQUIBB 06/23/2026
Columvi Glofitamab-Gxbm INJECTABLE;INTRAVENOUS 761309 GENETECH 06/18/2026
Absorica Isotretinoin CAPSULE;ORAL 021951 SUN PHARM INDS INC 06/16/2026
Keytruda Pembrolizumab SOLUTION;INTRAVENOUS 125514 MERCK SHARP DOHME 06/16/2026
Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa INJECTABLE;SOLUTION 761467 MERCK SHARP & DOHME LLC 06/16/2026
Skyrizi Risankizumab-Rzaa INJECTABLE;SUBCUTANEOUS 761262 ABBVIE INC 06/16/2026
Skyrizi Risankizumab-Rzaa INJECTABLE;INJECTION 761105 ABBVIE INC 06/16/2026
Welireg Belzutifan TABLET;ORAL 215383 MERCK SHARP DOHME 06/16/2026
Tzield Teplizumab INJECTION;SOLUTION 761183 PROVENTION BIO, INC. 06/15/2026
This email was sent to Esdek@podam.pl using Granicus Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA		 GovDelivery logo